Additionally, our analysis concluded that SGLT2 inhibitors reduced CVD and all-cause mortality significantly in non-ischemic HF but not in ischemic HF, with no significant subgroup differences between the two etiologies. This evidence concerns the gene SLC5A2 and hydrops fetalis.